Background: Gain-of-function mutations in transmembrane protein 173 (TMEM173) encoding stimulator of interferon genes (STING) underlie a recently described type I interferonopathy called STING-associated vasculopathy with onset in infancy (SAVI). Objectives: We sought to define the molecular and cellular pathology relating to 3 individuals variably exhibiting the core features of the SAVI phenotype including systemic inflammation, destructive skin lesions, and interstitial lung disease. Methods: Genetic analysis, conformational studies, in vitro assays and ex vivo flow-cytometry were performed. Results: Molecular and in vitro data demonstrate that the pathology in these patients is due to amino acid substitutions at positions 206, 281, and 284 of the human STING protein. These mutations confer cGAMP-independent constitutive activation of type I interferon signaling through TBK1 (TANK-binding kinase), independent from the alternative STING pathway
belonging to a recently defined class of disorders referred to as the type I interferonopathies. 9, 10 This phenotype, which is known as STING-associated vasculopathy with onset in infancy (SAVI), is characterized by early-onset systemic inflammation with fever, a severe skin vasculopathy that leads to extensive tissue loss in some cases, and interstitial lung disease resulting in pulmonary fibrosis and end-stage respiratory failure. [1] [2] [3] [4] [5] 7, 8 To date, 22 patients from 15 families have been reported with gain-of-function mutations in STING, [1] [2] [3] [4] [5] [6] [7] [8] a key adaptor molecule in the cytosolic DNA-sensing pathway expressed in various endothelial and epithelial cell types, as well as in hematopoietic cells, such as T cells, macrophages, and dendritic cells. Once stimulated, STING induces transcription of type I interferons and expression of a set of interferon-stimulated genes, thus establishing an antiviral state. [11] [12] [13] In all of these published cases, the heterozygous substitution involves one of 4 amino acids at positions 147, 154, 155, and 166 located either in the linker connecting the transmembrane domain of STING to the C-terminal cyclic dinucleotide-binding domain (CTD) (p.Val147) or within the N-terminal dimerization region of the CTD (p.Asn154, p.Val155, and p.Gly166). 14, 15 It has been suggested that these diseaseassociated residues play nonredundant roles in retaining the protein on the endoplasmic reticulum (ER), causing STING to constitutively localize to the ER-Golgi intermediate compartment and activate downstream signaling through the TANK-binding kinase 1 (TBK1)-Interferon regulatory factor 3 (IRF3) axis. 15, 16 We describe 3 subjects variably exhibiting the characteristic features of STING-associated autoinflammation. However, in contrast to earlier reports, our data show that the pathology in these patients is due to substitutions at positions 206, 281, and 284 of the human protein, thus implicating a novel region of STING as functionally important in the regulation of type I interferon signaling.
METHODS

Patient and study approval
The study was approved by the Comit e de Protection des Personnes (ID-RCB/EUDRACT: 2014-A01017-40) and undertaken with written informed parental consent.
Genetic analysis
DNA was extracted from whole blood samples by using standard methods. Whole-exome sequencing was performed on genomic DNA from patient 2 (P2) and her mother by using the SureSelect Human All Exon Kit (Agilent Technologies, Santa Clara, Calif) for targeted enrichment and the Illumina HiSeq2000 (Illumina, San Diego, Calif) for sequencing. Sanger sequencing was performed on DNA from P1, P3, and their parents and from P2 and her mother to confirm the variant found by using exome sequencing (primers are shown in Table E1 in this article's Online Repository at www.jacionline. org). Variant frequency data in control subjects was derived from the Exome Aggregation Consortium (ExAC). 17 
Structural analysis
The experimental 3-dimensional (3D) structures of STING were extracted from the Research Collaboratory for Structural Bioinformatics Protein Data Bank (PDB) and analyzed by using Chimera (https://www.cgl.ucsf.edu/ chimera/).
Construct generation
Site-directed mutagenesis was performed to generate the desired TMEM173 variants by using the Q5 Site-Directed Mutagenesis Kit (E0554S; New England Biolabs, Ipswich, Mass), according to the manufacturer's instructions. pMSCV-hygro(1; Addgene, Cambridge, Mass) carrying the wild-type (WT) TMEM173 gene was used as a template for the PCR reactions. 18 This plasmid carries the haplotype most frequently recorded in the general population (p.Arg71, p.Gly230, p.Arg232, and p.Arg293). 19 Mutagenic primer sequences were designed by using the NEBase Changer software (http://nebasechanger.neb.com/). Cycling parameters are indicated in Table E2 in this article's Online Repository at www.jacionline.org. NEB 5-alpha Competent Escherichia coli was transformed with the newly synthesized plasmid cDNA, and colonies were screened for the presence of the desired variants (primers are shown in Table E1 ).
Cell-culture procedures
Human embryonic kidney (HEK) 293T cells were grown in 96-well plates at 378C in 5% CO 2 in Dulbecco modified Eagle medium (#31966-021; Gibco, Carlsbad, Calif) supplemented with 10% (vol/vol) FBS (#10270; Gibco), 100 U/mL penicillin, and 100 mg/mL streptomycin (#15070-063; Gibco). At 70% confluency, HEK293T cells were cotransfected with 60 ng of vector pMSCV-hygro(1) either empty or encoding the TMEM173 variants, 40 ng of IFN-b promoter-driven firefly luciferase reporter plasmid (IFN-b-pGL3) and 1.4 ng of constitutively expressed Renilla luciferase reporter plasmid (pRL-TK) by using TransIT-293 (Mirus #MIR2700; Euromedex, Strasbourg, France). Twenty-four hours later, cells were stimulated by transfecting 1.3 to 12 mg/mL 2939-cyclic guanosine monophosphate (GMP)-AMP (cGAMP) _STING ligand (tlrl-nacga23; InvivoGen, San Diego, Calif) with Lipofectamine 2000 (#11668027; Thermo Fischer, Waltham, Mass). Twenty-four hours after cGAMP stimulation, cells were lysed with passive lysis buffer 5X (#E194A; Promega, Madison, Wis) containing protease and phosphatase inhibitors. One third of the lysate for each condition was used for the luciferase assay, and the remaining material was used for protein analysis by means of Western blotting.
Luciferase assay
The IFN-b-pGL3 plasmid was used to measure IFN-b promoter activity, and the Renilla reporter control plasmid was used to normalize for transfection efficiency. Luciferase assays were performed by using the Dual-Glo Luciferase Assay System (E2940; Promega), according to the manufacturer's protocol. Luminescence was acquired on a FLUOstar OPTIMA microplate reader (BMG LABTECH, Ortenberg, Germany). Firefly luciferase activity was normalized against Renilla luciferase activity.
Western blot
Bolt LDS Sample Buffer (4X; #B0008; Novex Life Technologies, Carlsbad, Calif) and Bolt Sample Reducing agent (10X; #B0009; Novex Life Technologies) were added to protein lysates, and samples were resolved on 
STAT1 phosphorylation assay staining
Ficoll PBMCs were treated or not with 1 mmol/L ruxolitinib for 45 minutes at 378C. Cells were fixed and permeabilized according to PerFix EXPOSE Kit (#B26976; Beckman Coulter, Fullerton, Calif) recommendations. Cells were stained for pSTAT1 phycoerythrin-anti-STAT1 pY701 and cell-surface markers (phycoerythrin-Cy7-CD19, allophycocyanin-CD3, and BV421-CD8) for 1 hour at room temperature. Flow cytometric analysis was performed on a Gallios Beckman Coulter flow cytometer. Results were analyzed with Kaluza software, version 1.3.
RESULTS
Clinical presentation
P1 (F1058) is a 7-year-old girl born to nonconsanguineous parents of white European ethnicity. She was delivered at term weighing 3.2 kg. She presented at age 3 months with feeding difficulties and respiratory distress necessitating oxygen therapy (Table I) . Computed tomography of the lungs at age 1.5 years revealed extensive ground-glass abnormalities, and there was interstitial fibrosis on lung biopsy without signs of vasculitis (Fig 1, A) . Telangiectatic skin lesions on the cheeks and nose were noted from the age of 4 months (Fig 1, B) . She has not experienced any involvement of the digits. Limited skin biopsy did not reveal any sign of vasculitis. Increased transaminase levels and hepatomegaly prompted a liver biopsy at age 2 years, when the presence of necrotizing granulomatous hepatitis was suggested (intralobular granulomas characterized by necrotizing zones with mixed inflammatory infiltrates). She has demonstrated no further evidence of liver disease. She had a gastrostomy fitted at age 2 years because of poor weight gain and subsequently experienced recurrent skin infections with poor healing around the entry site. In light of a continued oxygen requirement and increased levels of inflammatory markers, she was treated with immunosuppressants (steroids, methotrexate, and anti-TNF-a therapy) starting at age 23 months but with limited efficacy. She remains oxygen dependent with a severe deficit of lung function and markedly limited exercise tolerance.
P2 (F1125) is a 25-year-old woman born to nonconsanguineous parents of white European ethnicity. There is no family history of note. She demonstrated intrauterine growth retardation (birth weight at term, 23 SDs), with subsequent failure to thrive (adult height and weight of 143 cm and 34 kg, respectively), requiring a gastrostomy to be placed by age 1 year until puberty. She experienced recurrent bacterial infections of the upper respiratory tract, leading to severe septicemia at age 5 months (caused by Pseudomonas aeruginosa) and palatal and nasal septal necrosis. Results of screening for primary immune deficiencies were negative. A widespread livedo was noted from birth, which worsened gradually with an impressive purpuric aspect in patches on both the cheeks and buttocks and a marked dark purple marbling on the limbs (Fig 1, C) . When last seen at the age of 25 years, she had lost a large part of the external nares and demonstrated extreme acrocyanosis of the hands and feet. She has never experienced fevers, and systemic markers of inflammation and autoantibody titers have been consistently normal until recent antinuclear antibodies were detected at a low level (1/160). Lung function is normal. She is not currently treated. P3 (F1802) is a 15-year-old boy born to nonconsanguineous parents of white European ethnicity. A fixed erythema of the cheeks was noted shortly after birth. Telangiectasia of the cheeks, buttocks, and limbs was observed for the first time at age 10 years. From the age of 14 years, he had recurrent acrocyanosis moderately influenced by cold temperature, with painful acral erosions that heal as atrophic scars on the ear helices and digits. Lesional gluteal skin biopsies revealed dilated capillaries without obvious vasculitis or thrombosis. He has been treated with nifedipin, pentoxifylline, and acetyl salicylic acid, with limited efficacy. He has never experienced fevers or other features of systemic disease. Blood analysis, including markers of inflammation and autoantibody profile, has been consistently normal. Recent chest computed tomography revealed no evidence of interstitial lung disease. Lung function test and a 6-minute exercise tolerance test result were normal.
Identification of 3 new variants in STING
A summary of the molecular data relating to these 3 patients is presented in Fig 2 and Table I . A multiple sequence alignment of STING proteins from various species is provided in Fig E1 in this article's Online Repository at www.jacionline.org. 20, 21 P1 (F1058) was observed to carry a c.842G>A (p.Arg281Gln) variant in exon 7 of TMEM173 (Fig 2, A) , which has not been recorded on more than 120,000 control alleles on the ExAC database. Both parents were WT at this nucleotide, and microsatellite testing confirmed that the substitution had arisen de novo. The arginine at position 281 is conserved in the mouse but is an alanine in Xenopus tropicalis and a glutamate in Danio rerio. We note a similarly limited degree of conservation of the valine at position 147, substitution of which for a leucine has been previously shown to act as a gain-offunction mutation. 1 P2 (F1125) was observed to carry a c.850A>G (p.Arg284Gly) variant in exon 7 of TMEM173 (Fig 2, A) , which has not been recorded on more than 120,000 control alleles on the ExAC database. The mother was WT for this variant. DNA was not available from the father. The arginine is conserved to Nematostella vectensis. P3 (F1802) was observed to carry a c.617G>A (p.Cys206Tyr) variant in exon 6 of TMEM173 (Fig 2, A) , which has not been recorded on more than 120,000 control alleles on the ExAC database. Both parents were WT at this nucleotide, and microsatellite testing confirmed that the substitution had arisen de novo. The cysteine at this position is generally well conserved, except in Danio rerio, where it is replaced by an alanine.
3D structural analysis reveals a new mutation hotspot in STING
To gain further insight into the effect of the 3 STING substitutions we observed in the patients described above, we examined the experimental 3D structures of the CTD of STING (Fig 2, B) . p.Cys206 is buried within the 3D structure, whereas p.Arg281 and p.Arg284 lie on the surface of the protein. However, these 3 amino acids are in close proximity and are aligned, with p.Arg284 located between p.Cys206 and p.Arg281 (Fig 2, C  and D) . The substitution of the cysteine for a tyrosine is predicted to induce a steric clash, which might locally destabilize the 3D structure of the helix bundle and affect the positioning of the 281/284 arginine residues. reporter assay to measure their effect on type I interferon induction. 1, 15, 16 As previously shown, the p.Val155Met and p.Asn154Ser mutants induce reporter activity in the absence of ligand (Fig 2, E) . 1, 2, 15 We observed a similarly robust activation with patient-associated substitutions at p.Cys206Tyr, p.Arg281Gln, and p.Arg284Gly (Fig 2, E) , supporting the hypothesis that these variants are constitutively active.
To investigate whether these 3 variants lie within a novel functional cluster in STING, we went on to mutate other residues spatially close to the amino acids at 206, 281, and 284. Specifically, we changed p.Asp205 to p.Asp205Tyr and p.Asp205His, p.Leu265 to p.Leu265Tyr, p.Phe269 to p.Phe269Tyr, p.Gln273 to p.Gln273Ala and p.Gln273Leu, and p.Glu282 to p.Glu282Ala and p.Glu282Asp (Fig 3, A  and B) . 22 All these amino acids are exposed at the surface of the protein, except p.Leu265, which is buried and in contact with p.Cys206. In contrast to our patient-associated variants, substitution of any of these residues, except for the aspartate at position 205, behaved in a manner similar to WT (Fig 3, C , and see Table E3 in this article's Online Repository at www.jacionline.org). In contrast, substitution of the p.Asp205 resulted in an upregulation of IFN-b reporter activity as for the gain-of-function variants (Fig 3,  C , and see Table E3 ). Altogether, these results suggest the identification of a novel region implicated in STING regulation involving at least 4 amino acids. The fact that all of the different substitutions tested at these residues (2, 4, 3, and 3 at p.Asp205, p.Cys206, p.Arg281, and p.Arg284, respectively) result in increased IFN-b activity indicates that subtle conformational changes are sufficient to disrupt the normal control of the pathway. The specificity of this effect was emphasized by the fact that 4 other amino acids, p.Leu265, p.Phe269, p.Gln273, and p.Glu282, located in close proximity in the same tertiary structure did not induce a gain-offunction mutation when substituted.
STING gain-of-function mutations induced by p.Cys206Tyr, p.Arg281Gln, and p.Arg284Gly are independent of cGAMP binding Although all previously described STING-associated mutations are located close to the cGAMP binding site, the 3 novel mutations described here lie on the surface of the protein, without direct contact with this binding site (Fig 2, B) . To determine whether the gain of function observed in association with our new mutations resulted from ligand-independent constitutive activation or reflected an increased sensitivity to low levels of endogenous cGAMP, we generated double mutants involving the arginine at 232, which is essential for cGAMP binding. 14, 15 For every previously and newly described mutation, we observed a similarly robust upregulation of signaling, suggesting that despite clearly distinct localization in the tertiary structure, they all confer ligand-independent constitutive activation (Fig 4, A) .
Furthermore, using an antibody against phosphorylated residue p.Ser396 of IRF3, we recorded increased phosphorylation of IRF3 in cells expressing the 3 patient-associated mutations comparable with the previously described p.Val155Met. Consistent with our luciferase results, this increased IRF3 phosphorylation was not impaired by introducing a second mutation at p.Arg232Ala, which abrogates cGAMP binding and IRF3 phosphorylation in the WT state (Fig 4, B, STING gain of function induced by p.Cys206Tyr, p.Arg281Gln, and p.Arg284Gly is independent of the membrane fusion pathway Recently, it has been reported that a STING-dependent but cyclic GMP-AMP synthase-independent pathway can induce type I interferon expression in response to membrane fusion of enveloped RNA viruses. [24] [25] [26] In this model the arginine at 169 in human STING was shown to be important for stimulation of interferon expression by liposomes but not cGAMP, demonstrating that activation by these 2 stimuli can be mechanistically separated. p.Arg169 is surface exposed and located just outside the STING dimerization domain and facing away from the cGAMP-binding pocket. To determine whether the arginine at position 169 was crucial in the constitutive activation that we observed with our patient-associated mutations, we substituted an alanine for the WT arginine at 169 (p.Arg169Ala) and expressed the double mutants in our in vitro system. We observed no effect of the 169 substitution with mutations at 206, 281, and 284 or with the previously described mutations at 154 and 155, indicating that human disease-associated constitutive activation of STING is not dependent on this alternative pathway (Fig 5,  A) . A similar result was obtained with the double-mutant p.Asp205His and p.Arg169Ala (see Fig E2, B and E). Consistent with these data, constitutively activated constructs bearing the second mutation p.Arg169Ala demonstrated phosphorylated IRF3 at p.Ser396 in the basal state (Fig 5, B , and see Fig E2, B and E).
Constitutive activation of newly identified diseasecausing STING mutants is dependent on IRF3 phosphorylation
Phosphorylation of STING at p.Ser366 by TBK1 is critical for the recruitment and activation of IRF3 by STING and the subsequent activation of interferon signaling. 23, 27 To investigate whether SAVI-associated variants were dependent on TBK1-mediated STING phosphorylation and IRF3 recruitment, we introduced a mutation of serine to alanine at position 366 (p.Ser366Ala) into our mutant constructs. In all cases this substitution led to an abolition of IFN-b activation, despite similar expression of single and double STING mutants (Fig 6) . This was associated with loss of IRF3 phosphorylation, indicating that patient-associated mutations are dependent on phosphorylation at residue 366 for subsequent downstream activation of IRF3 (Fig 6, B , and see Fig E2, C and D) and transcription of interferon-stimulated genes.
STING constitutive activation leads to increased phosphorylation of STAT1 in T and B cells of P3 and normalize after ruxolitinib treatment in vitro
Type I interferons bind to a specific IFN-a receptor, thereby activating Janus kinase 1 and tyrosine kinase 2, which then induce phosphorylation of signal transducer and activator of transcription 1 (STAT1). We investigated STING constitutive activation in CD4, CD8, and CD19 cells from P3 and observed increased levels of STAT1 phosphorylation compared with those seen in a control subject (Fig 7) . Consistent with published data, this upregulation normalized after 45 minutes of treatment with ruxolitinib in vitro (Fig 7) . 1, 5 
DISCUSSION
Since its identification in 2008 as an adaptor molecule in the cytosolic DNA-sensing pathway, STING has emerged as a central player in antiviral immunity, autoinflammation, and cancer. 11, 13 Thus an understanding of the mechanism of action and control of STING in health and disease is of considerable scientific and medical importance.
Here we describe 3 novel variants seen in association with a phenotype consistent with previously described cases of STING-associated autoinflammation. In 2 of these patients, we were able to show that the amino acid substitutions arose de novo, whereas in the third patient the mother was WT but DNA was unavailable from the father. These substitutions, involving evolutionarily well-conserved residues, have not been described in publically available databases comprising more than 120,000 alleles. As for other molecularly confirmed cases of STINGassociated autoinflammation, all 3 substitutions were associated with the in vitro induction of IFN-b reporter activity. Considering these observations, it is very likely that the variants we describe represent pathogenic gain-of-function mutations.
In contrast to all previously published cases of type I interferonopathy related to mutations in STING, the 3 variants reported here do not lie in the linker region connecting the N-terminal transmembrane domain of STING to the CTD or in the first a-helix (a5) of the CTD involved in dimerization. The function of the arginine residues at 281 and 284 is currently undefined. However, these residues are exposed at the surface of the molecule, so that they are unlikely to involve the intramolecular interaction of the STING dimer. A recent survey of STING mutations in the Catalogue of Somatic Mutations in Cancer database led to the demonstration that a substitution of the arginine at 284 to methionine (p.Arg284Met) was able to induce an IFN-b reporter to a significantly greater extent than WT STING. 28 Alternative substitutions of arginine 284 for lysine or threonine (p.Arg284Lys and p.Arg284Thr) also represented hyperactive mutants. The results of these experiments were further supported by demonstrating increased IFN-b in tissue culture supernatants and an enhanced ability to inhibit viral replication. Of note, the mutation identified in P2 affects this same residue, substituting the arginine for a glycine. Thus multiple types of amino acid substitution at 284 confer a gain-of-function mutation, indicating a high degree of specificity for the function of an arginine at this position.
Similar to the arginine at 284, we found that different substitutions of the arginine at 281 and the cysteine at 206 also resulted in constitutive activation. It is of note that these 3 amino acids are aligned at the 3D level, with the arginine at 284 located between the cysteine at 206 and the arginine at 281. The substitution of the cysteine for a tyrosine at 206 is predicted to lead to steric hindrance and locally disturb the fold, which might affect the positioning of the arginine at 284. However, substituting other less bulky amino acids at 206 had the same effect, highlighting the specificity of the WT cysteine at this position.
To define the extent of a putative functionally important region involving the amino acids that we identified through human disease genetics, we went on to mutate a selection of other residues predicted to lie in close proximity to these diseaseassociated mutations, specifically p.Leu265, p.Phe269, p.Gln273, and p.Glu282. We also derived a number of conservative and nonconservative substitutions at Asp205, which lies in contact with p.Arg284. Substitutions at these residues behaved in a similar manner to WT protein, except for those at position 205, where we observed enhanced signaling in our in vitro assay similar to the patient-associated mutations. Of note, constitutive activation has been described previously at the equivalent residue in murine STING. 12, 29 In regard to cGAMP dependency the involvement of a cGAMP-independent signaling pathway and TBK1 downstream signaling, our data did not suggest any difference in the behavior of variants at 206, 281, and 284 compared with previously described disease-associated mutations at 147, 154, and 155. Recently, Dobbs et al 15 suggested that the latter mutations might disrupt the retention of STING in the ER, resulting in translocation to the ER-Golgi intermediate compartment and activation of TBK1/IRF3 in the absence of cGAMP binding. Furthermore, these mutations appeared to result in continued activation, presumably because of a failure of STING degradation. Our data clearly implicate a novel region of STING as important in type I interferon signaling, leading us to speculate that the surface-exposed arginine residues at 281 and 284 may also be involved in ER retention or in binding to a negative regulator of STING. 28 Our results indicate that mutations at residues 206, 281, and 284 of human STING are responsible for the disabling autoinflammation observed in the 3 patients we describe. Given the favorable effects seen with Janus kinase 1/2 inhibition in other patients with STING gain-of-function mutations, these patients might similarly benefit from such a therapeutic approach. 5 Alternative potential treatment strategies might include ER exit-blocking agents, palmitoylation inhibitors, or TBK1 antagonists. 15, [30] [31] [32] Considering that a p.Ser366Ala substitution abrogated the constitutive activation seen with every patientassociated mutation tested in our in vitro model, TBK1 blockade might be relevant to all patients with SAVI.
A major aspect of the pathology caused by mutations in TMEM173 appears to relate to a dysfunction of endothelium consequent on an upregulation of type I interferon signaling. The explanation for variable expression observed between and indeed within families will require further study, with such observations likely reflecting differential environmental exposures and/or modifying genetic factors. Indeed, although the cyclic GMP-AMP synthase-STING cytosolic DNA signaling pathway is essential for induction of an effective antiviral response, human genetics is teaching us about the risk of inflammatory disease associated with variation in this system. Polymorphisms in STING and other molecules involved in cytosolic nucleic acid recognition can confer differences in signaling to a type I interferon response: a nonbinary situation in which a balance is struck between antiviral priming and the risk of autoinflammation. 19, 33 Thus elucidation of the mechanisms of STING regulation is of great importance in understanding both microbial pathogenesis and inflammation. The findings presented here suggest a previously unappreciated aspect of the control of STING in this context. 
